In particular, PSMA represents an attractive target structure and proved suitable for highly sensitive and specific nuclear medicine imaging and therapy as it is overexpressed in almost all prostate carcinomas with markedly increased levels in metastases [1,2,3,4,5]. The gene discussed is FOLH1; the disease is prostate carcinoma.